![](\"https:\/\/mms.businesswire.com\/media\/20260521076927\/en\/2808807\/5\/Flatiron_Horizontal_RGB.jpg\")
<\/a><\/a>\nFlatiron\u2019s presence at ASCO 2026 closely follows the launch of Flatiron Telescope<\/a>, a multi-agent adaptive analytics platform designed to help life sciences teams find the right patients faster, assess study feasibility in real time, and generate oncology insights on demand. Flatiron Telescope will be demonstrated at the company\u2019s booth (#21149) for attendees to build and iterate on patient cohorts using natural language and generate insights in real time.<\/p> \n\"Our presence at ASCO 2026 proves that innovation and rigor aren't at odds\u2014they reinforce each other,\" said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. \"From digital twins that simulate patient outcomes to LLM-enabled treatment pattern analysis, our work demonstrates that Flatiron is defining\u2014not just participating in\u2014the evolution of oncology evidence. These 25+ acceptances showcase our unified, global oncology engine and reinforce our position as the gold standard in oncology intelligence, trusted to guide the highest-stakes decisions across the industry.\"<\/p> \nResearch highlights include:<\/p> \nJoin Flatiron Health at booth #21149 for a demo of Flatiron Telescope and follow Flatiron Health on X<\/a> and LinkedIn<\/a> for more updates from #ASCO26.<\/p> \nPoster Presentations\n \nExternal validation of a deep learning CT biomarker to predict first-line immune checkpoint inhibitor monotherapy-associated survival in PD-L1-high metastatic non-small cell lung cancer<\/b><\/a> \nPrognostic value of post-operative circulating tumor DNA (ctDNA) in real-world treatment and outcomes among patients (pts) with muscle invasive (MIBC) and locally advanced (LA) bladder cancer (BC)<\/b><\/a> \nReal-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era<\/b><\/a> \nComparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer<\/b><\/a> \nA risk stratification schema for patients with non-small cell lung cancer with multiple organ metastases<\/b><\/a> \nPlatinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomes<\/b><\/a> \nUsing ML to predict rapid progression for patients (pts) with HR+\/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4\/6 inhibitors (CDK 4\/6i)<\/b><\/a> \nRW post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with HR+\/HER2\u2212 metastatic breast cancer (MBC) in US.<\/b><\/a> \nRecurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer including early-onset disease<\/b><\/a> \nOnline Acceptances\n \nReal-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer<\/b><\/a> \nDrivers of organotropism and patterns of metastatic progression in metastatic non-small cell lung cancer<\/b><\/a>\n